IRIS Accounts Production v25.2.0.378 06485910 director 1.1.24 31.12.24 31.12.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh064859102023-12-31064859102024-12-31064859102024-01-012024-12-31064859102022-12-31064859102023-01-012023-12-31064859102023-12-3106485910ns15:EnglandWales2024-01-012024-12-3106485910ns14:PoundSterling2024-01-012024-12-3106485910ns10:Director12024-01-012024-12-3106485910ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3106485910ns10:SmallEntities2024-01-012024-12-3106485910ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-3106485910ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3106485910ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3106485910ns10:FullAccounts2024-01-012024-12-3106485910ns10:OrdinaryShareClass12024-01-012024-12-3106485910ns10:RegisteredOffice2024-01-012024-12-3106485910ns5:CurrentFinancialInstruments2024-12-3106485910ns5:CurrentFinancialInstruments2023-12-3106485910ns5:Non-currentFinancialInstruments2024-12-3106485910ns5:Non-currentFinancialInstruments2023-12-3106485910ns5:ShareCapital2024-12-3106485910ns5:ShareCapital2023-12-3106485910ns5:RetainedEarningsAccumulatedLosses2024-12-3106485910ns5:FurnitureFittings2024-01-012024-12-3106485910ns5:ComputerEquipment2024-01-012024-12-3106485910ns5:FurnitureFittings2023-12-3106485910ns5:ComputerEquipment2023-12-3106485910ns5:FurnitureFittings2024-12-3106485910ns5:ComputerEquipment2024-12-3106485910ns5:FurnitureFittings2023-12-3106485910ns5:ComputerEquipment2023-12-3106485910ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3106485910ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3106485910ns5:Secured2024-12-3106485910ns5:Secured2023-12-3106485910ns5:AcceleratedTaxDepreciationDeferredTax2024-12-3106485910ns5:AcceleratedTaxDepreciationDeferredTax2023-12-3106485910ns5:DeferredTaxation2023-12-3106485910ns5:DeferredTaxation2024-12-3106485910ns10:OrdinaryShareClass12024-12-31
REGISTERED NUMBER: 06485910 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 December 2024

for

Pharmalys Limited

Pharmalys Limited (Registered number: 06485910)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Pharmalys Limited

Company Information
for the Year Ended 31 December 2024







DIRECTOR: Ms M S Ba





REGISTERED OFFICE: Devonshire House
One Mayfair Place
London
W1J 8AJ





REGISTERED NUMBER: 06485910 (England and Wales)

Pharmalys Limited (Registered number: 06485910)

Balance Sheet
31 December 2024

31.12.24 31.12.23
as restated
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 18,047 19,203

CURRENT ASSETS
Debtors 5 210,906 426,048
Cash at bank 256 144,775
211,162 570,823
CREDITORS
Amounts falling due within one year 6 737,123 576,453
NET CURRENT LIABILITIES (525,961 ) (5,630 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(507,914

)

13,573

CREDITORS
Amounts falling due after more than one year 7 (4,166 ) (14,167 )

PROVISIONS FOR LIABILITIES 9 (1,849 ) (4,365 )
NET LIABILITIES (513,929 ) (4,959 )

CAPITAL AND RESERVES
Called up share capital 10 1 1
Retained earnings (513,930 ) (4,960 )
SHAREHOLDERS' FUNDS (513,929 ) (4,959 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Pharmalys Limited (Registered number: 06485910)

Balance Sheet - continued
31 December 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 1 September 2025 and were signed by:





Ms M S Ba - Director


Pharmalys Limited (Registered number: 06485910)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Pharmalys Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
The financial statements have been prepared on the going concern basis which assumes that the company will continue in operation for the foreseeable future. The director, who is the major creditors, have confirmed that she will continue to make sure funds as are needed by the company and in particular will not seek repayment from the amounts currently made available that would otherwise place the company in insolvency.

Based on this undertaking the director believes that the company will have sufficient resources to enable it to continue normal trading operation for a period of at least twelve months from the date of approval of these financial statements, and therefore it is appropriate to prepare the financial statements on a going concern basis.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on cost
Computer equipment - 25% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Pharmalys Limited (Registered number: 06485910)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 19 (2023 - 16 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 January 2024 6,537 77,179 83,716
Additions - 7,127 7,127
At 31 December 2024 6,537 84,306 90,843
DEPRECIATION
At 1 January 2024 6,346 58,167 64,513
Charge for year 191 8,092 8,283
At 31 December 2024 6,537 66,259 72,796
NET BOOK VALUE
At 31 December 2024 - 18,047 18,047
At 31 December 2023 191 19,012 19,203

Pharmalys Limited (Registered number: 06485910)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
as restated
£    £   
Trade debtors 96,040 270,430
Other debtors 114,866 155,618
210,906 426,048

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
as restated
£    £   
Bank loans and overdrafts 18,123 10,000
Trade creditors 20,861 28,497
Taxation and social security 235,529 199,133
Other creditors 462,610 338,823
737,123 576,453

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.12.24 31.12.23
as restated
£    £   
Bank loans 4,166 14,167

8. SECURED DEBTS

The following secured debts are included within creditors:

31.12.24 31.12.23
as restated
£    £   
Bank overdraft 8,123 -
Bank loans 14,166 24,167
22,289 24,167

The aggregate amount of creditors for which security has been given amounted to £14,166 (2023 - £24,167) and is supported by a guarantee from the UK Government to the bank under the Bounce Back Loan Scheme.

9. PROVISIONS FOR LIABILITIES
31.12.24 31.12.23
as restated
£    £   
Deferred tax
Accelerated capital allowances 1,849 4,365

Pharmalys Limited (Registered number: 06485910)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

9. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 January 2024 4,365
Accelerated capital allowances (2,516 )
Balance at 31 December 2024 1,849

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.12.24 31.12.23
value: as restated
£    £   
1 Ordinary £1 1 1

11. PENSION COMMITMENTS

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £12,007 (2023 - £11,553). Contributions totalling £1,884 (2023 - £4,410) were payable to the fund at the balance sheet date.

12. RELATED PARTY DISCLOSURES

At the balance sheet date, the balance due to the director was £123,925 (2023 - £168,657).